Advertisement

General Thoracic and Cardiovascular Surgery

, Volume 63, Issue 8, pp 446–452 | Cite as

A novel protocol for antibiotic prophylaxis based on preoperative kidney function in patients undergoing open heart surgery under cardiopulmonary bypass

  • Mizuho OdakaEmail author
  • Kenji Minakata
  • Hideaki Toyokuni
  • Kazuhiro Yamazaki
  • Atsushi Yonezawa
  • Ryuzo Sakata
  • Kazuo Matsubara
Original Article

Abstract

Objective

This study aimed to develop and assess the effectiveness of a protocol for antibiotic prophylaxis based on preoperative kidney function in patients undergoing open heart surgery.

Methods

We established a protocol for antibiotic prophylaxis based on preoperative kidney function in patients undergoing open heart surgery. This novel protocol was assessed by comparing patients undergoing open heart surgery before (control group; n = 30) and after its implementation (protocol group; n = 31) at Kyoto University Hospital between July 2012 and January 2013.

Results

Surgical site infections (SSIs) were observed in 4 control group patients (13.3 %), whereas no SSIs were observed in the protocol group patients (P < 0.05). The total duration of antibiotic use decreased significantly from 80.7 ± 17.6 h (mean ± SD) in the control group to 55.5 ± 14.9 h in the protocol group (P < 0.05). Similarly, introduction of the protocol significantly decreased the total antibiotic dose used in the perioperative period (P < 0.05). Furthermore, antibiotic regimens were changed under suspicion of infection in 5 of 30 control group patients, whereas none of the protocol group patients required this additional change in the antibiotic regimen (P < 0.05).

Conclusion

Our novel antibiotic prophylaxis protocol based on preoperative kidney function effectively prevents SSIs in patients undergoing open heart surgery.

Keywords

Antibiotic prophylaxis Cardiopulmonary bypass Renal function Surgical site infection 

Notes

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Morisaki A, Hosono M, Sasaki Y, Hirai H, Sakaguchi M, Nakahira A, et al. Evaluation of risk factors for hospital mortality and current treatment for poststernotomy mediastinitis. Gen Thorac Cardiovasc Surg. 2011;59:261–7.CrossRefPubMedGoogle Scholar
  2. 2.
  3. 3.
    Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27:97–132.CrossRefPubMedGoogle Scholar
  4. 4.
    Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg. 2001;20:1168–75.CrossRefPubMedGoogle Scholar
  5. 5.
    Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis. 2004;38:1357–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR, Society of Thoracic Surgeons. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part i: duration. Ann Thorac Surg. 2006;81:397–404.CrossRefPubMedGoogle Scholar
  7. 7.
    Gedney JA, Ghosh S. Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass. Br J Anaesth. 1995;75:344–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 2000;44:261–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Miller KW, McCoy HG, Chan KK, Fischer RP, Lindsay WG, Seifert RD, et al. Effect of cardiopulmonary bypass on cefazolin disposition. Clin Pharmacol Ther. 1980;27:550–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Kosaka T, Hosokawa K, Shime N, Taniguchi F, Kokufu T, Hashimoto S, et al. Effects of renal function on the pharmacokinetics and pharmacodynamics of prophylactic cefazolin in cardiothoracic surgery. Eur J Clin Microbiol Infect Dis. 2012;31:193–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, Edwards F, et al. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice. Ann Thorac Surg. 2007;83:1569–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Tegnell A, Arén C, Ohman L. Coagulase-negative staphylococci and sternal infections after cardiac operation. Ann Thorac Surg. 2000;69:1104–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Fariñas MC, Gald Peralta F, Bernal JM, Rabasa JM, Revuelta JM, González-Macías J. Suppurative mediastinitis after open-heart surgery: a case-control study covering a seven-year period in Santander, Spain. Clin Infect Dis. 1995;20:272–9.CrossRefPubMedGoogle Scholar
  14. 14.
    El Oakley RM, Wright JE. Postoperative mediastinitis: classification and management. Ann Thorac Surg. 1996;61:1030–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Holley FO, Ponganis KV, Stanski DR. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet. 1982;7:234–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Hillis DJ, Rosenfeldt FL, Spicer WJ, Stirling GR. Antibiotic prophylaxis for coronary bypass grafting. Comparison of a five-day and a two-day course. J Thorac Cardiovasc Surg. 1983;86:217–21.PubMedGoogle Scholar
  17. 17.
    Geroulanos S, Oxelbark S, Turina M. Perioperative antimicrobial prophylaxis in cardiovascular surgery. A prospective randomized trial comparing two day cefuroxime prophylaxis with four day cefazolin prophylaxis. J Cardiovasc Surg. 1986;27:300–6.Google Scholar
  18. 18.
    ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm. 1999;56:1839–88.Google Scholar
  19. 19.
    Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation. 2000;101:2916–21.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2015

Authors and Affiliations

  • Mizuho Odaka
    • 1
    • 3
    Email author
  • Kenji Minakata
    • 2
  • Hideaki Toyokuni
    • 1
  • Kazuhiro Yamazaki
    • 2
  • Atsushi Yonezawa
    • 1
  • Ryuzo Sakata
    • 2
  • Kazuo Matsubara
    • 1
  1. 1.Department of Clinical Pharmacology and TherapeuticsKyoto University HospitalKyotoJapan
  2. 2.Department of Cardiovascular SurgeryKyoto University HospitalKyotoJapan
  3. 3.Department of Pharmacy, University Hospital of MedicineTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations